Despite the proven tumorigenic role of SLC3A2 in a number of cancers including head and neck squamous cell carcinomas (HNSCC), it is also a novel therapeutic approach for advanced prostate cancer [51]. This evidence concerns the gene SLC3A2 and Familial prostate cancer.